文献速递老年与多病共存预防保健、筛查与疫苗

接种带状疱疹疫苗与痴呆风险降低相关

Lower dementia risk in patients vaccinated against herpes zoster.
PubMed 文献 · Ann Fam Med · 2022-04-01

两项回顾性队列(VHA 与 MarketScan)纳入≥65 岁无痴呆患者,比较接种与未接种带状疱疹疫苗者的痴呆发生率;调整混杂后接种与痴呆风险显著降低相关(VHA HR=0.69,95%CI 0.67-0.72;MarketScan HR=0.65,95%CI 0.57-0.74),且阿尔茨海默病风险亦降低。

要点

  • ≥65 岁接种带状疱疹疫苗者痴呆风险降低约 31-35%。
  • 接种与阿尔茨海默病风险降低相关,按种族未见差异。
  • 调整抗病毒药及带状疱疹感染后结果稳定。

核心结论

  • 在≥65 岁人群中,接种带状疱疹疫苗与痴呆风险降低 31-35% 相关。

研究设计与样本

  • 回顾性队列研究,VHA 队列 n=136,016,MarketScan 索赔队列 n=172,790,均≥65 岁且基线前两年无痴呆。

主要发现

  • VHA 队列接种 vs 未接种的痴呆 HR=0.69(95%CI 0.67-0.72),MarketScan 队列 HR=0.65(95%CI 0.57-0.74)。
  • 按种族未见结局差异,接种与阿尔茨海默病风险降低相关。
  • 调整抗病毒药及带状疱疹感染后结果稳定,E 值提示不能由选择偏倚或未测量混杂解释。

关键数值与推荐

  • VHA 队列平均年龄 75.6 岁(SD±7.5),女性 4%,白人 91.2%。
  • MarketScan 队列平均年龄 69.8 岁(SD±5.6),女性 65.4%。
  • 所有患者均有 3 次及以上『well visits』以控制预防保健服务利用相关混杂。

临床怎么用

  • 对≥65 岁患者,可将带状疱疹疫苗接种作为降低痴呆风险的潜在获益因素纳入讨论。

局限性

  • 需其他研究设计证实;结果可能由非特异性神经保护或免疫训练限制损伤性炎症解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Context: Herpes zoster (HZ) infection increases dementia risk but it is not known if HZ vaccination is associated with lower risk for dementia. Objective: Determine if patients with HZ vaccination vs. those who remain unvaccinated, have a lower risk for dementia in a cohort of Veterans Health Administration (VHA) patients. Replicate results in a private sector, medical claims patient cohort. Study Design: Retrospective cohort. Competing risk (VHA) and Cox proportional hazard (MarketScan) models estimated the association between HZ vaccination and incident dementia in all patients and in age (65-69, 70-74, ≥75) and race (White, Black, Other) sub-groups. Expanded models accounted for the effect of antivirals and HZ infection between index and end of follow-up. Sensitivity analysis measured the association between HZ vaccination and incident Alzheimer's dementia (AD). E-values computed to test for bias due to unmeasured confounding and selection bias. Setting/Data set: VHA cohort (10/1/2008 - 9/30/2019) with replication in MarketScan® commercial and Medicare claims (1/1/2009-12/31/2018). Population studied: Eligible patients (VHA n=136,016; MarketScan n=172,790) were ≥65 years of age and free of dementia for two years prior to baseline. All patients had 3 or more 'well visits' to control for confounding related to use of preventive health care services. Outcome measures: Incident dementia. Results: VHA patients were 75.6 (SD±7.5) years of age, 4% female, and 91.2% were white race. MarketScan patients were 69.8 (SD±5.6) years of age, on average and 65.4% were female. years of age on average, 65.0% were female. After controlling for confounding, HZ vaccination compared with no vaccination, was significantly associated with lower dementia risk (VHA HR= 0.69; 95%CI: 0.67-0.72; MarketScan HR=0.65; 95%CI:0.57-0.74). No difference in outcomes were observed by race and HZ vaccination was associated with lower AD risk. Results were stable after adjusting for antivirals and HZ infection. E-values indicated results are not explained by selection bias or unmeasured confounding. Conclusions: Among patients ≥65 years of age, HZ vaccination is associated with a 31-35% reduced risk of dementia. Confirmation in other study designs is warranted. Results may be explained by nonspecific neuroprotection and vaccination training the immune system to limit damaging inflammation. Results highlight the importance of HZ vaccination.

来源:Ann Fam Med,查看原文。版权归原作者所有。

引用

  1. Scherrer J, Salas J, Jacobs C, et al. Lower dementia risk in patients vaccinated against herpes zoster. Ann Fam Med. 2022. PMID: 36696249. doi:10.1370/afm.20.s1.2680

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。